Multiple Myeloma Research: Risks, benefits of stem cell transplant | Dana-Farber Cancer Institute

Dana-Farber research into autologous stem cell transplant for patients with multiple myeloma: study led by Dr. Paul G. Richardson, MD, found patients had dramatically increased progression-free survival, but were just as likely to be alive more than 6 years later if they chose to reserve their transplant until later. Press release: https://bit.ly/3cgaZ7l Video published: 7/14/22